Literature DB >> 9086149

Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge.

L W Church1, T P Le, J P Bryan, D M Gordon, R Edelman, L Fries, J R Davis, D A Herrington, D F Clyde, M J Shmuklarsky, I Schneider, T W McGovern, J D Chulay, W R Ballou, S L Hoffman.   

Abstract

To determine the characteristics of clinical illness accompanying Plasmodium falciparum infection induced by controlled exposure to infected mosquitoes, records of 118 volunteers participating in studies conducted between 1985 and 1992 were reviewed. One hundred fourteen volunteers (97%) reported at least one symptom attributable to malaria, with fatigue, myalgias or arthralgias, headache, and chills most commonly reported. The median duration of symptoms was 3 days. Fever was recorded in 61% of volunteers; 4 volunteers had temperatures >40 degrees C. Neutropenia and thrombocytopenia were present in 9% and 12% of volunteers, respectively. Despite counts as low as 658/microL (neutrophils) or 73,000/microL (platelets), no secondary infectious or hemorrhagic complications occurred. In all cases, volunteers recovered completely and laboratory values returned to baseline after specific antimalarial therapy. Recrudescence did not occur in any volunteer. In this model, mosquito inoculation of P. falciparum is a reliable, safe, and well-tolerated method of experimental challenge.

Entities:  

Mesh:

Year:  1997        PMID: 9086149     DOI: 10.1086/513990

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  57 in total

1.  Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials.

Authors:  J A Vaughan; L F Scheller; R A Wirtz; A F Azad
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects.

Authors:  David L Evers; Carol B Fowler; Jeffrey T Mason; Rebecca K Mimnall
Journal:  Sci Eng Ethics       Date:  2014-08-24       Impact factor: 3.525

3.  Ethical Criteria for Human Challenge Studies in Infectious Diseases.

Authors:  Ben Bambery; Michael Selgelid; Charles Weijer; Julian Savulescu; Andrew J Pollard
Journal:  Public Health Ethics       Date:  2015-09-27       Impact factor: 1.940

4.  Prevention and treatment of vivax malaria.

Authors:  J Kevin Baird; Eli Schwartz; Stephen L Hoffman
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

5.  White blood cell counts and malaria.

Authors:  F Ellis McKenzie; Wendy A Prudhomme; Alan J Magill; J Russ Forney; Barnyen Permpanich; Carmen Lucas; Robert A Gasser; Chansuda Wongsrichanalai
Journal:  J Infect Dis       Date:  2005-06-09       Impact factor: 5.226

Review 6.  Viral vector vaccines make memory T cells against malaria.

Authors:  Arturo Reyes-Sandoval; John T Harty; Stephen M Todryk
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

Review 7.  The development of a multivalent DNA vaccine for malaria.

Authors:  R C Hedstrom; D L Doolan; R Wang; M J Gardner; A Kumar; M Sedegah; R A Gramzinski; J B Sacci; Y Charoenvit; W R Weiss; M Margalith; J A Norman; P Hobart; S L Hoffman
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Determinants of MDA impact and designing MDAs towards malaria elimination.

Authors:  Bo Gao; Sompob Saralamba; Yoel Lubell; Lisa J White; Arjen M Dondorp; Ricardo Aguas
Journal:  Elife       Date:  2020-04-15       Impact factor: 8.140

9.  Plasmodium yoelii-infected A. stephensi inefficiently transmit malaria compared to intravenous route.

Authors:  Solomon Conteh; Rana Chattopadhyay; Charles Anderson; Stephen L Hoffman
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

10.  Cardiac complication after experimental human malaria infection: a case report.

Authors:  An-Emmie Nieman; Quirijn de Mast; Meta Roestenberg; Jorien Wiersma; Gheorghe Pop; Anton Stalenhoef; Pierre Druilhe; Robert Sauerwein; André van der Ven
Journal:  Malar J       Date:  2009-12-03       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.